BRCA1 and RAD51 methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study.

Authors

Helene Blons

APHP, European Georges Pompidou Hospital, Department of Biochemistry, Pharmacogenetics and Molecular Oncology, Paris Cancer Institute CARPEM, Paris, France

Helene Blons , Justine Abdelli , Valerie Taly , Claire Mulot , Pierre Laurent Puig , Benoit You , Philipp Harter , Domenica Lorusso , Yolanda Garcia , Christian Schauer , Sakari Hietanen , Nicoletta Colombo , Ignace Vergote , Hiroaki Kobayashi , Thibault De La Motte Rouge , Paul Buderath , Sabrina Chiara Cecere , Guillaume Bataillon , Eric Pujade-Lauraine , Isabelle Laure Ray-Coquard

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT02477644

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 5559)

DOI

10.1200/JCO.2023.41.16_suppl.5559

Abstract #

5559

Poster Bd #

254

Abstract Disclosures

FEATURED

BRCA1 and RAD51 methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study.

Authors

Helene Blons

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Clinical Trial Registration Number

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with olaparib/placebo maintenance in the phase III PAOLA-1/ENGOT-ov25 trial.

Poster

Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial.

Poster

Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance.

Poster

Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial.